228 related articles for article (PubMed ID: 29396245)
1. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
Rajendram R; Taylor PN; Wilson VJ; Harris N; Morris OC; Tomlinson M; Yarrow S; Garrott H; Herbert HM; Dick AD; Cook A; Gattamaneni R; Jain R; Olver J; Hurel SJ; Bremner F; Drummond SR; Kemp E; Ritchie DM; Rumsey N; Morris D; Lane C; Palaniappan N; Li C; Pell J; Hills R; Ezra DG; Potts MJ; Jackson S; Rose GE; Plowman N; Bunce C; Uddin JM; Lee RWJ; Dayan CM
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):299-309. PubMed ID: 29396245
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
5. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial.
Meggitt SJ; Gray JC; Reynolds NJ
Lancet; 2006 Mar; 367(9513):839-46. PubMed ID: 16530578
[TBL] [Abstract][Full Text] [Related]
6. Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial.
Rajendram R; Lee RW; Potts MJ; Rose GE; Jain R; Olver JM; Bremner F; Hurel S; Cook A; Gattamaneni R; Tomlinson M; Plowman N; Bunce C; Hollinghurst SP; Kingston L; Jackson S; Dick AD; Rumsey N; Morris OC; Dayan CM; Uddin JM
Trials; 2008 Jan; 9():6. PubMed ID: 18237441
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
9. Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.
Glover M; Smerdon GR; Andreyev HJ; Benton BE; Bothma P; Firth O; Gothard L; Harrison J; Ignatescu M; Laden G; Martin S; Maynard L; McCann D; Penny CEL; Phillips S; Sharp G; Yarnold J
Lancet Oncol; 2016 Feb; 17(2):224-233. PubMed ID: 26703894
[TBL] [Abstract][Full Text] [Related]
10. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
11. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
[TBL] [Abstract][Full Text] [Related]
12. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Warren RB; Mrowietz U; von Kiedrowski R; Niesmann J; Wilsmann-Theis D; Ghoreschi K; Zschocke I; Falk TM; Blödorn-Schlicht N; Reich K
Lancet; 2017 Feb; 389(10068):528-537. PubMed ID: 28012564
[TBL] [Abstract][Full Text] [Related]
13. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
[TBL] [Abstract][Full Text] [Related]
14. Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial.
Taylor P; Rajendram R; Hanna S; Wilson V; Pell J; Li C; Cook A; Gattamaneni R; Plowman N; Jackson S; Hills R; French R; Uddin JM; Lee RWJ; Dayan CM
J Clin Endocrinol Metab; 2023 Sep; 108(10):2615-2625. PubMed ID: 36971324
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
[TBL] [Abstract][Full Text] [Related]
16. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.
Banham GD; Flint SM; Torpey N; Lyons PA; Shanahan DN; Gibson A; Watson CJE; O'Sullivan AM; Chadwick JA; Foster KE; Jones RB; Devey LR; Richards A; Erwig LP; Savage CO; Smith KGC; Henderson RB; Clatworthy MR
Lancet; 2018 Jun; 391(10140):2619-2630. PubMed ID: 29910042
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial.
Knowles CH; Horrocks EJ; Bremner SA; Stevens N; Norton C; O'Connell PR; Eldridge S;
Lancet; 2015 Oct; 386(10004):1640-8. PubMed ID: 26293315
[TBL] [Abstract][Full Text] [Related]
19. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
